Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
CRNX Crinetics Pharmaceuticals, Inc. daily Stock Chart
CRNX [NASD]
Crinetics Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-1.27 Insider Own5.65% Shs Outstand24.35M Perf Week7.03%
Market Cap604.37M Forward P/E- EPS next Y-2.51 Insider Trans- Shs Float22.78M Perf Month-6.23%
Income-30.70M PEG- EPS next Q-0.46 Inst Own98.49% Short Float8.01% Perf Quarter11.15%
Sales2.40M P/S251.82 EPS this Y-169.40% Inst Trans4.55% Short Ratio30.34 Perf Half Y-3.91%
Book/sh6.32 P/B3.93 EPS next Y-30.70% ROA-20.80% Target Price39.50 Perf Year-
Cash/sh6.46 P/C3.84 EPS next 5Y- ROE-27.00% 52W Range19.23 - 42.00 Perf YTD-17.24%
Dividend- P/FCF- EPS past 5Y- ROI-17.90% 52W High-40.90% Beta-
Dividend %- Quick Ratio18.00 Sales past 5Y- Gross Margin- 52W Low29.07% ATR1.33
Employees47 Current Ratio18.00 Sales Q/Q0.00% Oper. Margin- RSI (14)51.53 Volatility6.63% 5.97%
OptionableNo Debt/Eq0.00 EPS Q/Q-50.70% Profit Margin- Rel Volume0.39 Prev Close24.67
ShortableYes LT Debt/Eq0.00 EarningsJun 12 AMC Payout- Avg Volume60.13K Price24.82
Recom2.00 SMA200.91% SMA50-1.08% SMA200-5.83% Volume23,513 Change0.61%
Feb-14-19Initiated H.C. Wainwright Buy $35
Aug-13-18Initiated Piper Jaffray Overweight $40
Aug-13-18Initiated Leerink Partners Outperform $43
Aug-13-18Initiated JP Morgan Neutral $29
May-21-19 07:30AM  Crinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors GlobeNewswire
May-13-19 04:11PM  Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
May-07-19 12:54PM  Heres What Hedge Funds Think About Crinetics Pharmaceuticals, Inc. (CRNX) Insider Monkey -5.67%
Mar-19-19 07:30AM  Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly GlobeNewswire
Mar-18-19 07:30AM  Crinetics Pharmaceuticals Appoints Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning GlobeNewswire
Mar-14-19 04:27PM  Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019 GlobeNewswire
Mar-13-19 04:05PM  Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Feb-21-19 07:30AM  Crinetics Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference GlobeNewswire -6.51%
Jan-16-19 10:16AM  Top 5 Small-Cap Winners And Losers, Week Of Jan. 7 Benzinga
Jan-08-19 12:50PM  At biotech's big event, a chance for execs to shape LGBTQ diversity on boards American City Business Journals
Jan-02-19 04:05PM  Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference GlobeNewswire
Nov-21-18 08:20AM  New Research Coverage Highlights Chuy's, Viveve Medical, ClearSign Combustion, WhiteHorse Finance, Crinetics Pharmaceuticals, and Boston Omaha Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire +9.88%
Nov-20-18 07:30AM  Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference GlobeNewswire
Nov-13-18 04:05PM  Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire +10.85%
Sep-26-18 04:05PM  Crinetics Pharmaceuticals to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology GlobeNewswire
Aug-30-18 04:07PM  Crinetics Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Jul-20-18 04:05PM  Crinetics Pharmaceuticals Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-19-18 08:00AM  Todays Research Reports on Stocks to Watch: CTI BioPharma and Crinetics Pharmaceuticals ACCESSWIRE -7.55%
Jul-18-18 11:37AM  Crinetics Pharmaceuticals stock surges 24% in trading debut MarketWatch
07:27AM  Crinetics Pharmaceuticals prices IPO at $17 a share MarketWatch
Jul-17-18 06:55PM  Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering GlobeNewswire
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and adrenocorticotrophic hormone antagonist for the treatment of cushing's diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
open in yahoo | open in reuters | open in google